GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (WBO:GLPG) » Definitions » Investments And Advances

Galapagos NV (WBO:GLPG) Investments And Advances : €13.6 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Galapagos NV Investments And Advances?

Galapagos NV's Investments And Advances for the quarter that ended in Dec. 2023 was €13.6 Mil.

Galapagos NV's quarterly Investments And Advances stayed the same from Jun. 2023 (€0.0 Mil) to Sep. 2023 (€0.0 Mil) but then increased from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€13.6 Mil).

Galapagos NV's annual Investments And Advances stayed the same from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) but then increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€13.6 Mil).


Galapagos NV Investments And Advances Historical Data

The historical data trend for Galapagos NV's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Investments And Advances Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.28 8.95 - - 13.58

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 13.58

Galapagos NV Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Galapagos NV (WBO:GLPG) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.